Question: What is the evidence that systemic adjuvant therapy is of benefit in patients with high-risk resected melanoma? In their study, Verma et al include patients with thick melanomas (at least 4.0 mm in thickness), Clark level V tumor, primary melanoma with in-transit metastases, primary melanoma with clinically apparent lymph node involvement or a positive sentinel lymph node biopsy result, resected lymph node disease with no known primary site, and current American Joint Committee on Cancer (AJCC) 2002 stage IIB, IIC, and III disease.
Tsai KY. Systemic Adjuvant Therapy for Patients With High-Risk Melanoma. Arch Dermatol. 2007;143(6):779–782. doi:10.1001/archderm.143.6.779